| pubmed-article:20674950 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20674950 | lifeskim:mentions | umls-concept:C0206754 | lld:lifeskim |
| pubmed-article:20674950 | lifeskim:mentions | umls-concept:C0205054 | lld:lifeskim |
| pubmed-article:20674950 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
| pubmed-article:20674950 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:20674950 | lifeskim:mentions | umls-concept:C0449258 | lld:lifeskim |
| pubmed-article:20674950 | lifeskim:mentions | umls-concept:C1550594 | lld:lifeskim |
| pubmed-article:20674950 | lifeskim:mentions | umls-concept:C0449446 | lld:lifeskim |
| pubmed-article:20674950 | lifeskim:mentions | umls-concept:C0183683 | lld:lifeskim |
| pubmed-article:20674950 | lifeskim:mentions | umls-concept:C1548760 | lld:lifeskim |
| pubmed-article:20674950 | lifeskim:mentions | umls-concept:C1547300 | lld:lifeskim |
| pubmed-article:20674950 | lifeskim:mentions | umls-concept:C0234227 | lld:lifeskim |
| pubmed-article:20674950 | lifeskim:mentions | umls-concept:C0580822 | lld:lifeskim |
| pubmed-article:20674950 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:20674950 | lifeskim:mentions | umls-concept:C0439807 | lld:lifeskim |
| pubmed-article:20674950 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:20674950 | pubmed:dateCreated | 2011-1-17 | lld:pubmed |
| pubmed-article:20674950 | pubmed:abstractText | Neuroendocrine neoplasms most commonly metastasize to the liver. Operative extirpation of neuroendocrine neoplasm hepatic metastases improves symptoms and seems to improve survival, but subsequent evidence is required. The current study evaluates the progression-free survival and overall survival of patients after resection (with or without ablation) of neuroendocrine neoplasm hepatic metastases. As a secondary endpoint, the prognostic factors associated with progression-free survival and overall survival were evaluated. | lld:pubmed |
| pubmed-article:20674950 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20674950 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20674950 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:20674950 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20674950 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:20674950 | pubmed:issn | 1532-7361 | lld:pubmed |
| pubmed-article:20674950 | pubmed:author | pubmed-author:MorrisDavid... | lld:pubmed |
| pubmed-article:20674950 | pubmed:author | pubmed-author:ZhaoJingJ | lld:pubmed |
| pubmed-article:20674950 | pubmed:author | pubmed-author:LiauwWinstonW | lld:pubmed |
| pubmed-article:20674950 | pubmed:author | pubmed-author:ChuFrancisF | lld:pubmed |
| pubmed-article:20674950 | pubmed:author | pubmed-author:ChuaTerence... | lld:pubmed |
| pubmed-article:20674950 | pubmed:author | pubmed-author:SaxenaAkshatA | lld:pubmed |
| pubmed-article:20674950 | pubmed:author | pubmed-author:SarkarAnikA | lld:pubmed |
| pubmed-article:20674950 | pubmed:copyrightInfo | Copyright © 2011 Mosby, Inc. All rights reserved. | lld:pubmed |
| pubmed-article:20674950 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20674950 | pubmed:volume | 149 | lld:pubmed |
| pubmed-article:20674950 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20674950 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20674950 | pubmed:pagination | 209-20 | lld:pubmed |
| pubmed-article:20674950 | pubmed:meshHeading | pubmed-meshheading:20674950... | lld:pubmed |
| pubmed-article:20674950 | pubmed:meshHeading | pubmed-meshheading:20674950... | lld:pubmed |
| pubmed-article:20674950 | pubmed:meshHeading | pubmed-meshheading:20674950... | lld:pubmed |
| pubmed-article:20674950 | pubmed:meshHeading | pubmed-meshheading:20674950... | lld:pubmed |
| pubmed-article:20674950 | pubmed:meshHeading | pubmed-meshheading:20674950... | lld:pubmed |
| pubmed-article:20674950 | pubmed:meshHeading | pubmed-meshheading:20674950... | lld:pubmed |
| pubmed-article:20674950 | pubmed:meshHeading | pubmed-meshheading:20674950... | lld:pubmed |
| pubmed-article:20674950 | pubmed:meshHeading | pubmed-meshheading:20674950... | lld:pubmed |
| pubmed-article:20674950 | pubmed:meshHeading | pubmed-meshheading:20674950... | lld:pubmed |
| pubmed-article:20674950 | pubmed:meshHeading | pubmed-meshheading:20674950... | lld:pubmed |
| pubmed-article:20674950 | pubmed:meshHeading | pubmed-meshheading:20674950... | lld:pubmed |
| pubmed-article:20674950 | pubmed:meshHeading | pubmed-meshheading:20674950... | lld:pubmed |
| pubmed-article:20674950 | pubmed:meshHeading | pubmed-meshheading:20674950... | lld:pubmed |
| pubmed-article:20674950 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:20674950 | pubmed:articleTitle | Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. | lld:pubmed |
| pubmed-article:20674950 | pubmed:affiliation | Department of Surgery, St George Hospital, The University of New South Wales, Kogarah, Sydney, Australia. | lld:pubmed |
| pubmed-article:20674950 | pubmed:publicationType | Journal Article | lld:pubmed |
